MALVERN, Pa.--(BUSINESS WIRE)--Velicept Therapeutics, Inc. announced today Clarence Young, M.D. has joined its leadership team as the company’s Chief Medical Officer. Dr. Young has nearly 30 years of experience in both large and small pharmaceutical companies and will bring his clinical development expertise to the advancement of solabegron, a highly selective beta 3-adrenoceptor agonist being developed for the treatment of overactive bladder (OAB).
“Dr. Young has outstanding experience in both early- and late-stage clinical development and has successfully developed, registered and commercialized new products,” said Dr. James Walker, Velicept President and Chief Executive Officer. “His medical leadership and regulatory experience will be of tremendous value for Velicept as we progress into phase two with our novel once-daily formulation of solabegron. The addition of Dr. Young rounds out our seasoned team which we view as a critical step in delivering on the full potential of solabegron to improve treatment alternatives for the large population of patients with OAB.”
Before joining Velicept, Dr. Young was Senior Vice-President and Chief Medical Officer at Iroko Pharmaceuticals, LLC, where he provided clinical and medical leadership for three NDA filings and approvals. He also has held executive leadership positions for Novartis and one of its acquisitions, Protez Pharmaceuticals, where he served as Vice President, Drug Development and Chief Medical Officer. Dr. Young began his pharmaceutical career at GlaxoSmithKline, where he was Vice President and Global Head, Anti-Infectives Clinical Development.
Dr. Young is a Fellow of the Infectious Diseases Society of America and served on the White House Working Group on Antimicrobial Resistance. He is a graduate of Williams College and Harvard Medical School and the author of numerous peer reviewed articles, reviews and scientific presentations.
About Velicept
Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead product, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). For more information, visit www.velicept.com.
